The European Commission approved Kimberly-Clark's $40 billion acquisition of Kenvue after the Kleenex maker agreed to sell its entire European feminine hygiene portfolio to a Turkish distributor, removing the last regulatory obstacle to a tie-up that combines Huggies with Tylenol.
The concessions
Kimberly-Clark committed to divest the Kotex brand, including its Lidie sub-brand, along with Camelia and Record, across the European Economic Area. The Commission said the transaction would otherwise have eliminated an important supplier in the tampon market, with particular competitive harm identified in the Czech Republic, Estonia and Slovakia.
The buyer
Turkey-based Dilek Gida Uretim, a distributor of consumer goods brands, agreed to purchase the divested assets. The Commission cleared Dilek as a suitable purchaser, citing its financial resources and operational expertise to maintain and develop the business. The approval of the divestiture itself was a separate decision.
What the filing does not say
The Commission statement gives no detail on the consideration type for the main acquisition, the premium to Kenvue's undisturbed price, or any break fee or material adverse change condition. Kimberly-Clark's stated rationale, that the combination creates a stronger consumer health platform, is presented as a claim, not a verified outcome.
What to watch
The deal now moves to closing, where the focus shifts to whether Dilek can operate the divested brands as a standalone competitor in the three flagged markets. The Commission's remedy approval is conditional on Dilek's ability to replicate Kimberly-Clark's supply chain and distribution reach, a test that will play out after the transaction completes.